全文获取类型
收费全文 | 900499篇 |
免费 | 74617篇 |
国内免费 | 1963篇 |
专业分类
耳鼻咽喉 | 13313篇 |
儿科学 | 25604篇 |
妇产科学 | 25583篇 |
基础医学 | 129117篇 |
口腔科学 | 25899篇 |
临床医学 | 79535篇 |
内科学 | 172392篇 |
皮肤病学 | 17404篇 |
神经病学 | 74017篇 |
特种医学 | 36785篇 |
外国民族医学 | 171篇 |
外科学 | 143852篇 |
综合类 | 24921篇 |
现状与发展 | 3篇 |
一般理论 | 317篇 |
预防医学 | 70191篇 |
眼科学 | 21188篇 |
药学 | 67160篇 |
中国医学 | 1625篇 |
肿瘤学 | 48002篇 |
出版年
2018年 | 9166篇 |
2016年 | 7848篇 |
2015年 | 9147篇 |
2014年 | 13158篇 |
2013年 | 19179篇 |
2012年 | 26449篇 |
2011年 | 27491篇 |
2010年 | 15802篇 |
2009年 | 14697篇 |
2008年 | 25167篇 |
2007年 | 27297篇 |
2006年 | 26721篇 |
2005年 | 26117篇 |
2004年 | 25441篇 |
2003年 | 24275篇 |
2002年 | 23197篇 |
2001年 | 35981篇 |
2000年 | 36586篇 |
1999年 | 31053篇 |
1998年 | 9446篇 |
1997年 | 8710篇 |
1996年 | 8601篇 |
1995年 | 8116篇 |
1994年 | 7806篇 |
1992年 | 26719篇 |
1991年 | 26139篇 |
1990年 | 25648篇 |
1989年 | 24720篇 |
1988年 | 23253篇 |
1987年 | 22921篇 |
1986年 | 21771篇 |
1985年 | 21134篇 |
1984年 | 16422篇 |
1983年 | 14027篇 |
1982年 | 8889篇 |
1981年 | 8226篇 |
1980年 | 7703篇 |
1979年 | 16750篇 |
1978年 | 12129篇 |
1977年 | 10193篇 |
1976年 | 9340篇 |
1975年 | 10161篇 |
1974年 | 12660篇 |
1973年 | 12155篇 |
1972年 | 11553篇 |
1971年 | 10697篇 |
1970年 | 10227篇 |
1969年 | 9916篇 |
1968年 | 8905篇 |
1967年 | 8232篇 |
排序方式: 共有10000条查询结果,搜索用时 19 毫秒
61.
David M. Presby Michael C. Rudolph Vanessa D. Sherk Matthew R. Jackman Rebecca M. Foright Kenneth L. Jones Julie A. Houck Ginger C. Johnson Janine A. Higgins P. Darrell Neufer Robert H. Eckel Paul S. MacLean 《Diabetes》2021,70(4):867
Moderate weight loss improves numerous risk factors for cardiometabolic disease; however, long-term weight loss maintenance (WLM) is often thwarted by metabolic adaptations that suppress energy expenditure and facilitate weight regain. Skeletal muscle has a prominent role in energy homeostasis; therefore, we investigated the effect of WLM and weight regain on skeletal muscle in rodents. In skeletal muscle of obesity-prone rats, WLM reduced fat oxidative capacity and downregulated genes involved in fat metabolism. Interestingly, even after weight was regained, genes involved in fat metabolism were also reduced. We then subjected mice with skeletal muscle lipoprotein lipase overexpression (mCK-hLPL), which augments fat metabolism, to WLM and weight regain and found that mCK-hLPL attenuates weight regain by potentiating energy expenditure. Irrespective of genotype, weight regain suppressed dietary fat oxidation and downregulated genes involved in fat metabolism in skeletal muscle. However, mCK-hLPL mice oxidized more fat throughout weight regain and had greater expression of genes involved in fat metabolism and lower expression of genes involved in carbohydrate metabolism during WLM and regain. In summary, these results suggest that skeletal muscle fat oxidation is reduced during WLM and regain, and therapies that improve skeletal muscle fat metabolism may attenuate rapid weight regain. 相似文献
62.
63.
64.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
65.
Gastro-oesophageal reflux disease (GORD) is symptomatic reflux of gastric contents into the oesophagus. Factors predisposing to GORD are loss of the physiological antireflux barrier and anatomic abnormalities of the oesophagus or diaphragm. Conservative measures and medical management results in resolution of symptoms in a majority of children. Surgery is indicated in the event of failure of medical management or severe complications. Surgical procedures include open or laparoscopic fundoplication in children with normal neurology; fundoplication with or without vagotomy and pyloroplasty; surgical feeding jejunostomy and oesophago-gastric dissociation in the severely neurologically impaired children. 相似文献
66.
Joobin Sattar Adi Kartolo Wilma M. Hopman Joshua Matthew Lakoff Tara Baetz 《Journal of Geriatric Oncology》2019,10(3):411-414
ImportanceImmunotherapy has emerged as an effective treatment option for the management of advanced cancers. The effects of these immune checkpoint inhibitors in the older patient population has not been adequately assessed.ObjectiveTo understand the impact of aging on CTLA-4 and PDL-1 inhibitors efficacy and immune-related adverse events (irAE) in the context of real-world management of advanced solid cancers.Design, Setting, and ParticipantsThis retrospective study involved all non-study patients with histologically-confirmed metastatic or inoperable solid cancers receiving immunotherapy at Kingston Health Sciences Centre. We defined ‘older patient’ as age ≥ 75. All statistical analyses were conducted under SPSS IBM for Windows version 24.0.Main Outcomes and MeasuresStudy outcomes included immunotherapy treatment response, survival, as well as number, type, and severity of irAEs.ResultsOur study (N = 78) had 29 (37%) patients age <65, 26 (33%) patients age 65–74, and 23 (30%) patients age ≥75. Melanoma, non-small cell lung cancer, and renal cell carcinoma accounted for 70%, 22%, and 8% of the study population, respectively. Distributions of ipilimumab (32%), nivolumab (33%), and pembrolizumab (35%) were similar in the study. The response rates were 28%, 27%, and 39% in the age <65, age 64–74, age ≥75 groups, respectively (P = 0.585). Kaplan-Meier curve showed a median survival of 28 months (12.28–43.9, 95% CI) and 17 months (0–36.9, 95% CI) in the age <65 and age 64–74 groups, respectively; the estimated survival probability did not reach 50% in the age ≥75 group (P = 0.319). There were no statistically significant differences found in terms of irAEs, multiple irAEs, severity of grade 3 or higher, types of irAEs, and irAEs resolution status when comparing between different age groups.Conclusion and RelevanceOur results suggest that patients age ≥75 are able to gain as much benefit from immunotherapy as younger patients, without excess toxicity. Our findings suggest that single agent immunotherapy is generally well-tolerated across different age groups with no significant difference in the type, frequency or severity of irAEs. Future studies evaluating aging and combination immunotherapy are warranted. 相似文献
67.
68.
69.
70.